Pfizer Corporation

Bristol-myers Squibb Compnay

Schering Corporation

E. R. Squibb Sons, Inc.

Medarex Inc.

Leland Stanford Junior University

Merck Sharp + Dohme Corp.

Peter Brams

Haichun Huang

Brigitte Devaux

Kristopher Toy

Arvind Rajpal

Dawn M Tanamachi

Josephine M Cardarelli

Leonard G Presta

Mohan Srinivasan

Heidi N Leblanc

Denise Leah Williams

Jonathan A Pachter

Ronald P Gladue

Lan Yang

Yan Wang

Barrett Richard Thiele

Yanli Wu

Wei Liao

Yi Wu

Robert Greenberg

Rory Francis Finn

Timothy J Paradis

Judith Hailey

Diane Feingersh

Jing Min

Jun Zhang

Alan J Korman

Alison Witte

David B Passmore

Karla Ann Henning

Eric H Holmes

Amelia Nancy Black

Michelle Renee Kuhne

Tetsuya Ishino

Robert Arch

Joel Bard

Cynthia A Vistica

Madhav Narasimha Devalaraja

William Finlay

Orla Cunningham

Ciara Reilly

Steven Lee Bender

Haibin Chen

Mark Yamanaka

Michael Aidan North

Gerald Fries Casperson

Dana Dan Hu-Lowe

Xin Jiang

Gang Li

Tim Sproul

Jianying Wang

Brian K Kobilka

Leonard Presta

Grant Wickman

Asna Masood

Michelle M Mader

Dan Rohrer

Michelle Madar

Michelle Kuhne

Michelle Mader

Ronald Paul Gladue

Timothy Joseph Paradis

Amelia Black

Tim W Sproul

The present invention provides antibodies, or antigen-binding fragment thereof, which specifically bind to tumor necrosis factor (TNF)-like ligand (TL1A). The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of TL1A mediated diseases, disorders or conditions.

Tumor necrosis factor-like ligand 1A specific antibodies and compositions and uses thereof

The present invention provides antibodies, or antigen-binding fragment thereof, which specifically bind to tumor necrosis factor (TNF)-like ligandA(TLA) The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of TLA mediated diseases, disorders or conditions.

The present disclosure provides isolated monoclonal antibodies that specifically bind to CXCR4 with high affinity, particularly human monoclonal antibodies. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting CXCR4, as well as methods for treating various cancers, inflammatory disorders and HIV infection using an anti-CXCR4 antibody of this disclosure.

Human monoclonal antibodies that bind CXCR4 and uses thereof

The present disclosure provides isolated binding molecules that bind to the human OX40R, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions.

Binding molecules to the human OX40 receptor

Nucleic acids encoding human monoclonal antibodies that bind CXCR4

The present invention provides antibodies, or antigen-binding fragment thereof, which specifically bind to tumor necrosis factor-like ligand 1A (TL1A). The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of TL1A mediated diseases, disorders or conditions.

The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to Fucosyl-GM1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting Fucosyl-GM1, as well as methods for treating various diseases, including cancer, using anti-Fucosyl-GM1 antibodies.

Human monoclonal antibodies to fucosyl-GM1 and methods for using anti-fucosyl-GM1 antibodies

The invention provides transgene constructs for expressing chimeric antibodies, and transgenic non-human host animals carrying such constructs, wherein the chimeric antibodies comprise human variable regions and constant regions of the non-human transgenic host animal. The presence of immunoglobulin constant regions of the host animal allows for generation of improved antibodies in such transgenic host animals. Subsequently, the chimeric antibodies can be readily converted to fully human antibodies using recombinant DNA techniques. Thus, the invention provides compositions and methods for generating human antibodies in which chimeric antibodies raised in vivo in transgenic mice are used as intermediates and then converted to fully human antibodies in vitro.

Transgenic animals expressing chimeric antibodies for use in preparing human antibodies

Human monoclonal antibodies to Fucosyl-GM1 and methods for using anti-Fucosyl-GM1 antibodies

Antibodies and antigen-binding portions thereof that bind to human IL-6 are provided. Also provided are nucleic acids encoding such antibodies and antigen binding portions, methods of making such antibodies and antigen binding portions, compositions comprising such antibodies or antigen binding portions, and uses of such antibodies or antigen binding portions.

Antibodies to IL-6 and their uses

Human monoclonal antibodies that bind CXCR4

The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, or antigen binding portions thereof, that specifically bind to integrin &#x3b1;5&#x3b2;1 with high affinity. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies or antigen binding portions thereof are also provided. The disclosure also provides methods for treating various cancers using the anti-&#x3b1;5&#x3b2;1 antibodies or antigen binding portions thereof described herein.

Alpha5-beta1 antibodies and their uses

Growing community of inventors

Sacramento, CA, United States of America

Peter Brams